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Abstract. Ebola virus disease (EVD) is a life-threatening zoonosis caused by infection with the Ebola virus. Since the
first reported EVD outbreak in the Democratic Republic of the Congo, several small outbreaks have been reported in
central Africa with about 2,400 cases occurring between 1976 and 2013. The 2013–2015 EVD outbreak in west Africa is
the first documented outbreak in this region and the largest ever with over 27,000 cases and more than 11,000 deaths.
Although EVD transmission rates have recently decreased in west Africa, this crisis continues to threaten global health
and security, particularly since infected travelers could spread EVD to other resource-limited areas of the world. Because
vaccines and drugs are not yet licensed for EVD, outbreak control is dependent on the use of non-pharmaceutical inter-
ventions (e.g., infection control practices, isolation of EVD cases, contact tracing with follow-up and quarantine, sanitary
burial, health education). However, delays in diagnosing and reporting EVD cases in less accessible rural areas continue to
hamper control efforts. New advances in rapid diagnostics for identifying presumptive EVD cases and in mobile-based
technologies for communicating critical health-related information should facilitate deployment of an early response to
prevent the amplification of sporadic EVD cases into large-scale outbreaks.
We live in a globally interconnected world where the rapidity
of modern travel allows us, and the microbes that infect us, to
be virtually anywhere within only hours. In earlier times, weeks
or months were often needed to traverse the barriers that were
imposed by geography and distance. The lengthiness of travel
afforded some protection against the introduction of virulent
pathogens to new locales because many who were infected
either recovered or succumbed before reaching their final
destination. This is no longer the case. Several tropical viral
diseases (e.g., dengue, Middle East respiratory syndrome,
chikungunya, and Ebola virus disease [EVD]) have expanded
their geographical range due in part to transit of infected
humans.1 Of these diseases, EVD has received the lion’s share
of international attention. This is because of the 2013–2015
EVD outbreak in west Africa where over 27,000 cases with
more than 11,000 deaths have been reported.2 Although EVD
transmission rates have decreased and Liberia was recently
declared free of EVD transmission by the World Health
Organization (WHO), this crisis continues to threaten global
health and security.
EVD is caused by infection with a single-stranded, negative-
sense RNA virus of the genus Ebolavirus.3 Zaire ebolavirus
(EBOV) was first identified in humans in an outbreak that
occurred in 1976 near the Ebola River in the Democratic
Republic of the Congo (DRC, formerly Zaire).4 Three addi-
tional African species, Sudan, Tai Forest, and Bundibugyo
ebolavirus, also cause disease in humans, but the case fatality
rates due to infection with these viruses are not as high as that
due to EBOV, which can reach 90%. Although the natural
reservoir of Ebola virus has not been definitively determined,
serological and molecular data indicate that this virus is pres-
ent in some species of African frugivorous and insectivorous
bats.5–7 Zoonotic transmission of Ebola virus may occur in
humans who are exposed during hunting and butchering of
infected bats.5,8 Increases in human population, coupled with
changes in land use, enhance the risk of contact with reser-
voirs of Ebola virus.8 Pigott and others6 mapped the zoonotic
niche of EVD in central and west Africa and reported that
22 million humans inhabit at-risk areas. It is possible that
EVD could spread more readily in these areas because of
increasing population growth and mobility.
Human-to-human transmission of EVD occurs primarily via
direct contact with bodily fluids of an infected human after
fever has developed or with the body of a human who has
recently died of EVD.3 The incubation period usually lasts
about 1 week, but can be 3 weeks or possibly longer. Thus,
humans who are incubating disease, but not yet symptomatic,
can travel a considerable distance before they begin to
shed the virus as demonstrated by the introduction of EVD
via ground travel (e.g., Guinea to Liberia, Sierra Leone, and
Senegal) and via air travel (e.g., Guinea to the United States;
Liberia to Nigeria, the United States, and the United Kingdom;
Sierra Leone to Italy).2,9,10
Although the current EVD outbreak has waned, infections
are still occurring in some hot spots in west Africa. Because of
the international connectivity of west Africa, there is concern
that EVD could spread to other densely populated, resource-
limited areas of the world that are ill-prepared to control
this disease for which there is as yet no licensed vaccine or
proven curative therapy.10–13 Halting EVD transmission is crit-
ical to prevent further spread of EVD within and beyond west
Africa. The use of multifaceted non-pharmaceutical interven-
tions (e.g., infection control practices, EVD treatment units
for case isolation, contact tracing with follow-up and quaran-
tine, sanitary burial, health education) has decreased EVD
transmission in many areas of west Africa. Nevertheless, delays
in diagnosing and reporting new EVD cases in less accessible
rural areas continue to hamper control efforts.14
If control interventions had been deployed early on, the
EVD outbreak in west Africa may have been contained in a
relatively short time similar to some EVD outbreaks that
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occurred previously in central Africa.15,16 Unfortunately, the
lack of surveillance for EVD in west Africa, a region that
was largely unfamiliar with this disease, and the lack of
adequate public health capacity, impeded an early response
and allowed the establishment of multiple foci of EVD in
Guinea. However, there is hope that new advances in rapid
diagnostics and mobile-based communication technology will
expedite the deployment of resources to control EVD out-
breaks.1,17,18 Rapid diagnosis of EVD is critical because the
early symptoms of EVD (i.e., high fever, malaise, fatigue,
body aches) can be confused with those of some other
endemic infectious diseases (e.g., malaria, influenza, typhoid,
dengue, yellow fever, Lassa fever).19,20 The WHO recently
approved the ReEBOV Antigen Rapid Test, developed by
Tulane University researchers (New Orleans, LA) in partner-
ship with Corgenix Inc. (Broomfield, CO), for procurement in
EVD-affected countries.21 This lateral flow immunochromato-
graphic assay can provide results within 15–25 minutes and is
based on the qualitative detection of EBOV VP40 antigen in
serum, plasma, or finger-stick whole blood.22 Although less
accurate (92% sensitivity; 85% specificity) than “gold stan-
dard” nucleic acid amplification tests (NAATs), the ReEBOV
Antigen Rapid Test is less expensive, easier to perform, and
does not require electricity. With appropriate infection control
precautions, the ReEBOV Antigen Rapid Test can be used
by trained personnel as a screening tool in rural health clinic
settings for presumptive detection of EBOV in patients whose
signs and symptoms, in conjunction with epidemiological risk
factors, are consistent with EVD. Rapid diagnosis of pre-
sumptive EVD cases allows for 1) isolation of symptomatic
individuals while they await confirmatory NAAT to prevent
health-care-associated EVD; 2) quarantine and monitoring of
contacts to prevent spread of EVD to the community; 3) early
administration of supportive treatments (i.e., rehydration, elec-
trolytes, antibiotics, antimalarials) to improve patient outcome;
and 4) timely engagement of affected communities to reduce
fear and to encourage cooperation with control interventions.
However, because of the lower specificity of the ReEBOV
Antigen Rapid Test, further refinements will be necessary to
improve its positive predictive value when EVD case numbers
are low to reduce exposure of patients with false positive test
results to patients with EVD. The U.K.’s Defense Science and
Technology Laboratory (DSTL) has developed a rapid diag-
nostic test (RDT) that is similar in principle to the ReEBOV
Antigen Rapid Test, but is based on detection of an undis-
closed Ebola virus antigen.23 The DSTL EVD RDT can
produce a semiquantitative result by scoring the test (T) line
on color intensity (2–10). Although the DSTL EVD RDT
appears to have high sensitivity (100%) with a specificity of
(∼92–97%) compared with NAAT (i.e., when the control and
T line (CT) score is above 2, 4, or 6), further studies are
needed before this test can be approved for screening pur-
poses. Other RDTs for EVD are in various stages of develop-
ment. For example, researchers at the Massachusetts Institute
of Technology (Cambridge, MA) and Harvard Medical School
(Boston, MA) engineered a multiplexed pathogen detection
platform that uses multicolored silver nanoparticles conjugated
to monoclonal antibodies directed against EBOV, dengue
virus, or yellow fever virus to detect the presence of these
agents in human serum.24 Further development of this experi-
mental device, with inclusion of monoclonal antibodies
directed against malaria, a common endemic infection, may
result in a rapid screening test that could aid differential diag-
nosis of febrile patients who are suspected to have EVD.
Once presumptive EVD cases have been identified, they
must be promptly reported to public health authorities to
quickly mobilize resources for outbreak control. Advances in
mobile-based communication technology are enabling faster,
cheaper, and more reliable reporting of EVD cases with
expanded geographic coverage. One of several promising exam-
ples is mHero (mobile Health Worker Electronic Response and
Outreach), a new, two-way, mobile communication platform.25
IntraHealth International (Chapel Hill, NC), in partnership
with the United Nations Children’s Fund and Liberia’s Ministry
of Health and Social Welfare (MOHSW), has deployed mHero
to help frontline health workers (HWs) respond to EVD out-
breaks. mHero enables Liberia’s MOHSW to instantly send
critical information to thousands of HWs’ mobile phones and
HWs to send time-sensitive information to the MOHSW. This
powerful tool allows for reporting and tracking of new EVD
cases, communicating laboratory test results, sharing reference
and training materials, testing and improving HWs’ knowledge,
and coordinating with rural health clinics. IntraHealth is intro-
ducing mHero in Guinea and discussions are underway to roll
out mHero to other countries in west Africa.
In addition to expediting EVD case reporting, advances in
mobile-based communication technology could help to track
the spread of EVD. Accurate, near real-time information on
population mobility in west Africa, one of the most highly
connected and densely populated regions of Africa, could
show where people have gone after leaving an area of EVD
transmission, thus suggesting where new cases might appear.
This information is valuable because it enables public health
authorities to rapidly focus intervention efforts to interrupt
EVD transmission. Only a decade ago, obtaining detailed and
comprehensive data for this region would have been impossi-
ble. Today, call data records (CDRs) that contain mobility
data are stored on cell phone carrier servers. Although CDRs
have yet to be released for Guinea, Liberia, and Sierra Leone,
the west African countries most affected by the EVD out-
break, mobility pattern models have been generated for Côte
d’Ivoire and Senegal to demonstrate the feasibility of this
approach, which has been previously used to track the spread
of malaria in Kenya and cholera in Haiti.26
Thus far, more than 24 outbreaks of EVD have occurred in
Africa since the first documented outbreak in the DRC in
1976. The 2013–2015 EVD outbreak in west Africa is a stark
reminder that an emerging infectious disease can exact a terri-
ble toll on human life, severely affect health-care systems, dev-
astate fragile economies, and destabilize governments. Because
Ebola virus has an animal reservoir, it cannot be eradicated.
Zoonotic introduction of Ebola virus into the African popula-
tion will continue to occur and must be detected and tackled
early on at the source to prevent amplification of sporadic
EVD cases into large-scale outbreaks that are driven by
human to human transmission.7,27 Improved rapid diagnostics
and mobile-based communication technology are critical to
enable a swift response to EVD and must be included in the
EVD preparedness response. Finally, the current EVD out-
break has highlighted the urgent need to rebuild the greatly
weakened public health infrastructure of EVD-affected west
Africa. This will require a long-term international commitment
of significant financial and technical resources. Nonetheless,
investments along these lines will surely pay off many times
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over for global health by strengthening west Africa’s capacity
to mount an early response to control outbreaks of EVD and
other emerging infectious diseases.
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